Mostrar el registro sencillo del ítem

dc.contributor.authorSaravia, Rocío
dc.contributor.authorTen Blanco, Marc
dc.contributor.authorGrande Rodríguez, Mª Teresa 
dc.contributor.authorMaldonado, Rafael
dc.contributor.authorBerrendero, Fernando 
dc.date.accessioned2019-01-14T12:51:39Z
dc.date.available2019-01-14T12:51:39Z
dc.date.issued2018
dc.identifier.issn0889-1591spa
dc.identifier.urihttp://hdl.handle.net/10641/1552
dc.description.abstractNicotine withdrawal is associated with cognitive deficits including attention, working memory, and episodic memory impairments. These cognitive deficits are a hallmark of nicotine abstinence which could be targeted in order to prevent smoking relapse. The underlying mechanisms, however, are poorly understood. In this study, memory impairment was observed in mice 4 days after the precipitation of nicotine withdrawal by the nicotinic antagonist mecamylamine. The presence of cognitive deficits correlated with microglial activation in the hippocampus and the prefrontal cortex. Moreover, an increased expression of neuroinflammatory markers including IL1β, TNFα and IFNγ was found in both memory-related brain regions. Notably, flow cytometric analysis also revealed an enhancement of TNFα and IFNγ plasmatic levels at the same time point during nicotine withdrawal. Impaired neurogenesis, as shown by reduction in the expression of the endogenous cell proliferation marker Ki67 and the early neuron marker doublecortin, was also associated with nicotine abstinence. Treatment with the non-psychoactive cannabinoid cannabidiol abolished memory impairment of nicotine withdrawal and microglia reactivity, reduced the expression of IL1β and IFNγ in the hippocampus and the prefrontal cortex, respectively, and normalized Ki67 levels. The nonsteroidal anti-inflammatory drug indomethacin also prevented cognitive deficits and microglial reactivity during withdrawal. These data underline the usefulness of anti-inflammatory agents to improve cognitive performance during early nicotine abstinence.spa
dc.language.isoengspa
dc.publisherBrain, Behavior, and Immunityspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectNicotinespa
dc.subjectWithdrawalspa
dc.subjectMicrogliaspa
dc.subjectCytokinesspa
dc.subjectCannabidiolspa
dc.subjectIndomethacinspa
dc.titleAnti-inflammatory agents for smoking cessation? Focus on cognitive deficits associated with nicotine withdrawal in male mice.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dc.rights.accessRightsopen accessspa
dc.description.extent372 KBspa
dc.identifier.doi10.1016/j.bbi.2018.11.003spa


Ficheros en el ítem

FicherosTamañoFormatoVer
berrendero.pdf371.2KbPDFVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España